This is the authors' abstract. We don't add key points for this paper.
Introduction Alcohol is the most used drug in the United States and places a significant burden on our health care system. Nowhere is this impact more evident than in our emergency departments (EDs), where more than 4 million visits and 178,000 deaths related to alcohol occurred in 2023.1 A complication of alcohol use disorder (AUD) is alcohol withdrawal syndrome (AWS). Clinical presentations vary in severity and range from tremors and autonomic hyperactivity to agitation, auditory or visual hallucinations, and seizures. The mainstays of management for AWS are GABA agonists, specifically benzodiazepines.2,3 However, the 2020 American Society of Addiction Medicine (ASAM) Alcohol Withdrawal Management Guidelines also highlight that “phenobarbital is an appropriate alternative for providers experienced with its use,” supporting the use of phenobarbital as monotherapy and/or adjunct therapy.3-6 While many providers have experience with phenobarbital in the management of AWS, heterogeneity exists as it relates to route of administration, dosing strategies, and patient selection. Herein, we summarize the drug characteristics, primary literature, and suggested role of phenobarbital for management of moderate to severe AWS in the ED.Drug Characteristics Like benzodiazepines, phenobarbital is a GABA-A receptor agonist. Unlike benzodiazepines, however, it does not rely on endogenous GABA to function, which may be advantageous for individuals with AUD and nutritional deficits. Phenobarbital is supplied as a tablet and injectable solution, with maximum available strengths of 100 mg and 130 mg/mL, respectively.7,8 It may be administered orally (PO), intramuscularly (IM), or intravenously (IV) for the management of AWS, providing symptom burden relief within 60, 30, and 5 minutes, respectively.9 Phenobarbital possesses a long half-life, ranging from 50 to 150 hours.7,8 This may support patients through the duration of withdrawal and create an “auto taper” effect.10 Safety is a common concern with phenobarbital use. Phenobarbital is a strong cytochrome P450 (CYP) enzyme inducer; thus, it is potentially associated with multiple drug-drug interactions.7,8 However, clinical applicability in the ED is not well described. Additionally, phenobarbital is considered contraindicated in the setting of acute intermittent porphyria or fulminant liver failure, and in patients with a documented hypersensitivity to phenobarbital, phenytoin, carbamazepine, or oxcarbazepine.7,8,11-13 Concerns of over sedation and respiratory depression are also frequently cited.3 However, these claims were extrapolated from literature pertaining to management of status epilepticus where larger doses are used.14 Recent systematic reviews and meta-analysis assessing phenobarbital use for AWS have described no increased risk when compared to benzodiazepines.15,16 Patient Evaluation Obtaining a detailed history of the patient's time of last drink, typical frequency and quantity of alcohol consumption, complications during prior withdrawal episodes (seizures, delirium tremens, etc), and past medical history is crucial for initial management. Next, a Clinical Institute Withdrawal Assessment for Alcohol Revised (CIWA-Ar) should be performed to assess the severity of AWS.3 Limitations exist with this scoring tool, because it is subjective, takes time to administer, may be confounded by comorbidities, and requires that the patient to be able to cooperate and communicate. For patients who are unable to participate, a RIKER Sedation-Agitation Scale (SAS) score or Richmond Agitation Sedation Scale (RASS) score may be more appropriate to use.3 If patients meet criteria for moderate to severe or complicated AWS or possess risk factors for severe disease, our goal should be to quickly control their symptoms and prevent the progression of disease. Table 1 describes criteria and risk factors for moderate to severe AWS.3,17-19 Table 1 - Populations Who May Benefit from Phenobarbital Administration3,17-19 Population Details Moderate AWS Defined as a CIWA-Ar 10-18 Severe AWS Defined as a CIWA-Ar ≥19 Complicated AWS Defined as a CIWA-Ar ≥19 and seizures, signs or symptoms of delirium, or new onset auditory hallucinations or visual hallucinations Benzodiazepine intolerance/resistant Patients who develop delirium or paradoxical reactions when challenged with benzodiazepines, those with tolerance/resistance, or those receiving ≥40 mg of diazepam in 1 hour Risk factors for severe disease History of alcohol withdrawal seizures or delirium, numerous prior withdrawal episodes, comorbid medical or surgical illness, age >65 years, prolonged duration of heavy and regular alcohol consumption, seizures during the current withdrawal episode, and physiologic dependence on other GABAergic agents Abbreviations: AWS, alcohol withdrawal syndrome; CIWA-Ar, Clinical Institute Withdrawal Assessment for Alcohol Revised. Treatment Phenobarbital was first used to treat AWS in the 1920s; however, its use halted in the 1960s with the development of oxazepam and chlordiazepoxide.3 Resurgence of use occurred after studies demonstrated safety in addition to a reduction in the occurrence of mechanical ventilation, intensive care unit (ICU) admissions, ICU length of stay, and benzodiazepine requirements when compared to standard of care with benzodiazepines.14, 20-22 Various phenobarbital dosing strategies (Table 2) were used to corroborate these findings. These include: 1) a high-dose, front loaded (10 mg/kg IV infused over 30 minutes) approach; 2) a fixed-dose, front-loaded (60-260 mg PO/IM) regimen; and 3) a fixed-dose, symptom-triggered (260 mg IV, then 130 mg IV every 30 minutes) strategy. Table 2 - Potential Phenobarbital Dosing Strategies in the Emergency Department3,21-23 Dosing strategies Dosing strategy subtype Dosing regimen Associated outcomes Monotherapy High-dose, front-loaded 10 mg/kg IV infused over 30 min Reduction in ICU admission rates Decreased benzodiazepine requirements Reduction in mechanical ventilation Fixed-dose, front-loaded 60-260 mg po/IM Fixed-dose, symptom triggered 260 mg IV, then 130 mg IV every 30 min at provider's discretion Reduce modified CIWA from baseline to ED discharge Adjunct therapy High-dose, front-loaded 10 mg/kg IV over 30 min Adapted from the 2020 ASAM Guidelines.Abbreviations: CIWA, clinical institute withdrawal assessment; ED, emergency department; ICU, intensive care unit; IV, intravenously; kg: kilograms; mg: milligrams These studies informed the 2020 ASAM Alcohol Withdrawal Guidelines, which provide guidance on monotherapy and adjunct use of phenobarbital.14,20-22 Specifically, monotherapy phenobarbital may be used if patients have a contraindication to benzodiazepines for the management of mild, moderate, or severe AWS or in settings where patients are at risk of severe or complicated AWS (Table 1).3 Phenobarbital may also be used as an adjunct therapy to benzodiazepines for risk management or treatment of severe or complicated AWS.3Table 2 outlines dosing strategies described in the guidelines and outcomes associated with each regimen. Since the release of these guidelines, two systematic reviews have further highlighted the limitations with available literature due to the heterogeneity in the patient populations, dosing strategies, and primary outcomes evaluated.15,16 Lee et al found no reduction in ICU admissions, hospital admissions, ED readmissions, or adverse events with phenobarbital use for AWS in the ED when compared to benzodiazepines.15 Meanwhile, Punia et al found lower odds of a subsequent ED visit, decreased benzodiazepine use, and reduced ICU admission rates with phenobarbital use.16 There is discordance between the findings of each systematic review, though when considering the totality of the current body of literature, phenobarbital seems to be a safe and practical option to incorporate in the early management of AWS. When deciding upon which phenobarbital dosing strategy to pursue, we believe the best approach would be to opt for a high-dose, front-loaded strategy (10 mg/kg IV infused over 30 minutes) in combination with symptom-triggered benzodiazepines (diazepam or lorazepam) for moderate to severe AWS or those with risk factors for severe disease (Table 1). We suggest this dosing strategy due to a combination of practical workflow considerations, the drug characteristics, and findings supported by Rosenson et al.21 The high-dose, front-loaded strategy (10 mg/kg IV infused over 30 minutes) avoids dose stacking that may occur with administration of small aliquots orally, intramuscularly, or intravenously.23 Specifically, Shah et al compared high-dose front-loaded (10 mg/kg IV infused over 30 minutes) to low-dose, intermittent strategies (260 mg intravenous push × 1 followed by 130 mg intravenous push every 15 minutes as needed) and found patients in the low-dose, intermittent strategy were 4.4 times more likely to require mechanical ventilation.23 It also reduces nursing workload by avoiding the need for frequent administration (ie, every 30 minutes). Furthermore, intravenous phenobarbital in comparison to intramuscular or oral administration provides the quickest symptom burden relief, prevents AWS progression, and reduces morbidity and mortality.9 These findings are further supported when we consider the long half-life, lipophilicity, mechanism of action, and ability to adequately saturate GABA-A receptors with phenobarbital.7,8 Lastly, this regimen in combination with symptom-triggered benzodiazepines has been found to decrease ICU admission rates and decrease the total amount of benzodiazepines required during patient admissions.21 Summary In conclusion, phenobarbital is an underutilized safe and effective treatment option for management of AWS. Various phenobarbital dosing strategies exist. However, we suggest adopting a high-dose, front-loaded approach in combination with symptom-triggered benzodiazepines for management of moderate to severe AWS, or in patients with risk factors for severe disease. Phenobarbital has been shown to decrease benzodiazepine requirements, ICU admissions, mechanical ventilation rates, and potentially mortality. Additionally, phenobarbital has the potential to drastically alter the clinical trajectory of alcohol withdrawal patients admitted to our health care systems.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Harris et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: